Announcements Trials
Browse Landscape

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 10Observational 2

Sponsor

Cancer Type

Tumor-Agnostic 2

Conditions

Breast Neoplasms 3Neoplasms 2Recurrent Squamous Cell Lung Carcinoma 1

Interventions

Surveys and Questionnaires 86Blood Specimen Collection 58Interviews as Topic 28Observation 15Data Collection 15Radiotherapy 12Watchful Waiting 11Magnetic Resonance Spectroscopy 11Hematologic Tests 11Exercise 11Drug Therapy 11Quality of Life 9Biopsy 8Specimen Handling 7Therapeutics 6Restraint, Physical 6Magnetic Resonance Imaging 6Focus Groups 6pembrolizumab 5Standard of Care 5Rivaroxaban 5Phlebotomy 5Nivolumab 5Lapatinib 5Immune Checkpoint Inhibitors 5atezolizumab 4apixaban 4Trastuzumab 4Patient Reported Outcome Measures 4Palliative Care 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Neoplasms × talazoparib × Clear all
NCT04774406 2023-06-06

Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

University Hospital, Caen

Completed
2,336 enrolled
Tumor-Agnostic

Neoplasms

NCT04774627 2021-09-23

Pancytopenia Related to PARP Inhibitors (PancytoRIB)

University Hospital, Caen

Completed
200 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡